Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$5.43
+0.08 (+1.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $312.9M · quality 72.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.6B
P/E
20.9x
↑EV/EBITDA
6.1x
↓ROE
6.2%
↑Gross Margin
37.0%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.8%
FCF CAGR
-9.5%
FCF margin
22.0%
FCF / Net income
1.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.54B · net income $393.2M · FCF $776.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.54B | $3.54B | $4.07B | $5.03B | $5.15B |
| Net Income | $393.2M | $393.2M | $481.9M | $567.3M | $574.4M |
| EBITDA | $780.8M | $780.8M | $897.4M | $1.04B | $1.07B |
| EPS | 0.28 | 0.28 | 0.35 | 0.41 | 0.41 |
| Gross Margin | 37.0% | 37.0% | 37.9% | 37.1% | 36.6% |
| Operating Margin | 20.3% | 20.3% | 20.0% | 20.4% | 18.2% |
| Net Margin | 11.1% | 11.1% | 11.8% | 11.3% | 11.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.58 | 6.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $776.7M | $776.7M | $271.5M | $312.9M | $1.05B |
| Returns | |||||
| ROE | 6.2% | 6.2% | 7.8% | 9.5% | 10.0% |
| Valuation | |||||
| P/E | 20.88 | 20.88 | 15.98 | 16.36 | 15.34 |
| EV/EBITDA | 6.08 | 6.08 | 5.99 | 6.41 | 5.60 |
| P/B | 1.19 | 1.19 | 1.25 | 1.55 | 1.54 |
| Growth & Yield | |||||
| Revenue Growth | -13.2% | -13.2% | -19.0% | -2.3% | — |
| EPS Growth | -18.9% | -18.9% | -14.8% | -1.2% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
19.8%
EPS terminal req.
$0.48
Spread vs growth
-38.8%
5Y implied EPS CAGR
15.8%
EPS terminal req.
$0.58
Spread vs growth
-34.7%
10Y implied EPS CAGR
12.9%
EPS terminal req.
$0.94
Spread vs growth
-31.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.3%
Start / end P/E
16.0x → 19.4x
EPS bridge
0.35 → 0.28
Residual
-4.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.